Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/32162

Title:	Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
Authors:	Poveda, A Del Campo, J M Ray-Coquard, I Alexandre, J Provansal, M Guerra Alía, E M Casado, A Gonzalez-Martin, A Fernández, C Rodriguez, I Soto, A Kahatt, C Fernández Teruel, C Galmarini, C M Pérez de la Haza, A Bohan, P Berton-Rigaud, D View more
Keywords:	lurbinectedin ovarian cancer platinum resistant topotecan View more
Mesh:	Aged Antineoplastic Agents Carbolines Female Heterocyclic Compounds, 4 or More Rings Humans Ovarian Neoplasms Platinum Topotecan View more
Issue Date:	1-Jun-2017
Citation:	Ann. Oncol..2017 Jun;(28)6:1280-1287
Abstract:	PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer.
PMID:	28368437
URI:	https://hdl.handle.net/20.500.12530/32162
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5452066.pdf		274.16 kB	Adobe PDF	View/Open